Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Enzymatica

3,03

 

SEK

 

0 %

Mindre end 1K følgere

ENZY

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus

Enzymatica is a life science company that develops and sells medical devices for infection-related diseases. The products are based on barrier technology, which includes marine enzymes. The company's first product is ColdZyme® Mouth Spray which can prevent colds as well as shorten the illness period. The product has been launched on several markets and the strategy is to expand to more markets via partners. The company is headquartered in Lund.

Læs mere
Markedsværdi
735,49 mio. SEK
Aktieomsætning
184,47 t SEK
Omsætning
45,58 mio.
EBIT %
-114,22 %
P/E
-
Udbytteafkast, %
-
Finanskalender
17.7
2025

Delårsrapport Q2'25

30.10
2025

Delårsrapport Q3'25

18.2
2026

Årsrapport '25

Alle
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper
Pressemeddelelse14.5.2025, 13.10

BioStock: The science behind ColdZyme – Insights from professors

Enzymatica
Selskabsmeddelelse7.5.2025, 13.44

Bulletin from the annual general meeting of Enzymatica AB (publ) on May 7, 2025

Enzymatica
Pressemeddelelse5.5.2025, 09.15

Enzymatica AB: BioStock: Enzymatica gears up for global expansion after a strong first quarter

Enzymatica

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Selskabsmeddelelse29.4.2025, 06.30

Enzymatica AB: Quarterly report Q1/2025: Enzymatica strengthens its position in home markets and focuses on international expansion

Enzymatica
Selskabsmeddelelse2.4.2025, 12.45

Notice of Annual General Meeting 2025 in Enzymatica AB (publ)

Enzymatica
Pressemeddelelse11.3.2025, 07.15

Enzymatica AB: BioStock: Enzymatica's results published in The Journal of Physiology

Enzymatica
Pressemeddelelse6.3.2025, 11.02

Enzymatica AB: Replay Link to Digital Press Briefing - March 5, 2025

Enzymatica
Pressemeddelelse28.2.2025, 16.30

Enzymatica AB: Invitation to Press Briefing - 5 March 2025

Enzymatica
Selskabsmeddelelse28.2.2025, 15.00

Enzymatica AB: New independent studies show that ColdZyme addresses the root cause of respiratory infections, reducing sick days and symptoms

Enzymatica
Pressemeddelelse25.2.2025, 08.27

Enzymatica AB: BioStock: Enzymatica boosts Q4 revenue but sees room for stronger partner sales

Enzymatica
Selskabsmeddelelse18.2.2025, 07.30

Enzymatica AB: Year-end report 2024: Strong performance in core markets - preparing for international growth

Enzymatica
Pressemeddelelse14.1.2025, 09.20

Enzymatica AB: BioStock: Enzymatica recruits experienced marketing director

Enzymatica
Pressemeddelelse9.1.2025, 10.00

Enzymatica AB: Enzymatica focuses on growth with new recruitment - Anna Söderlund joins as Senior Director Marketing & Sales

Enzymatica
Selskabsmeddelelse7.11.2024, 07.30

Enzymatica AB: Interim report Q3/2024: Focus on developing existing and new markets

Enzymatica
Selskabsmeddelelse12.9.2024, 16.21

Enzymatica AB: Enzymatica announces outcome of new rights issue

Enzymatica
Pressemeddelelse12.9.2024, 09.09

Enzymatica AB: BioStock: Final study results - ColdZyme reduces illness duration and alleviates symptoms

Enzymatica
Selskabsmeddelelse9.9.2024, 13.07

Enzymatica AB: Enzymatica publishes supplementary prospectus

Enzymatica
Selskabsmeddelelse5.9.2024, 18.30

Enzymatica AB: Reported results on secondary endpoints from the University of Kent study on ColdZyme® show significant reduction of symptoms, lost training days and viral load

Enzymatica
Selskabsmeddelelse26.8.2024, 10.29

Enzymatica AB: Publication of prospectus regarding Enzymatica's rights issue

Enzymatica
Selskabsmeddelelse16.8.2024, 13.30

Enzymatica AB: Final results from independent clinical study of ColdZyme® show duration of illness lowered by approximately 5 days.

Enzymatica
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.